Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)
Phase 2
Completed
NCT05660538
| Condition | Diabetic Peripheral Neuropathy |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Vertex Pharmaceuticals Incorporated |
|---|
| Status | Completed |
|---|
| Enrollment | 194 participants |
|---|
| Interventions | Suzetrigine, Pregabalin, Placebo (matched to SUZ), Placebo (matched to pregabalin) |
|---|
| Start date | Dec 20, 2022 |
|---|
| Completion date | Oct 12, 2023 |
|---|
| Results posted | Jul 1, 2025 |
|---|
Summary
The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating Painful DPN.
Change From Baseline in the Weekly Average of Daily Pain Intensity on a Numeric Pain Rating Scale (NPRS)
Baseline, At Week 12 · units on a scale
| Pregabalin | -2.09 units on a scale |
|---|
| Suzetrigine (SUZ): Low Dose | -2.18 units on a scale |
|---|
| Suzetrigine (SUZ): Mid Dose | -2.11 units on a scale |
|---|
| Suzetrigine (SUZ): High Dose | -2.26 units on a scale |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.